1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. SAUDI ARABIA ANTI-RHEUMATIC DRUG MARKET BY TYPE OF DISEASE
5.1. Introduction
5.2. Osteoarthritis
5.3. Rheumatoid Arthritis
5.4. Gout
5.5. Lupus
5.6. Others
6. SAUDI ARABIA ANTI-RHEUMATIC DRUG MARKET BY DRUG CLASS
6.1. Introduction
6.2. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
6.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.4. Corticosteroids
6.5. JAK inhibitor
6.6. Others
7. SAUDI ARABIA ANTI-RHEUMATIC DRUG MARKET BY SALES CHANNEL
7.1. Introduction
7.2. Prescription
7.3. Over-The-Counter (OTC)
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Market Share Analysis
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Competitive Dashboard
9. COMPANY PROFILES
9.1. Novartis Pharmaceuticals Corporation
9.2. Eli Lilly and Company
9.3. Pfizer Inc.
9.4. GlaxoSmithKline plc
9.5. Sanofi S. A
9.6. Johnson & Johnson
9.7. Hikma Pharmaceuticals Plc
9.8. Jamjoom Pharma
9.9. AbbVie Inc.
9.10. Amgen Inc.
10. APPENDIX
10.1. Currency
10.2. Assumptions
10.3. Base and Forecast Years Timeline
10.4. Key benefits for the stakeholders
10.5. Research Methodology
10.6. Abbreviations